Ansari, M. A. et al. (2019) Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. eLife, 8, e42463. (doi: 10.7554/eLife.42463) (PMID:31478835) (PMCID:PMC6721795)

Wing, P. A.C. et al. (2019) Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir. Gastroenterology, 157(3), 692-704.e9. (doi: 10.1053/j.gastro.2019.05.007) (PMID:31078622)

da Silva Filipe, A. et al. (2018) Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". Journal of Hepatology, 68(4), pp. 864-866. (doi: 10.1016/j.jhep.2017.11.044) (PMID:29339112)

McLauchlan, J. , Innes, H., Dillon, J.F., Foster, G., Holtham, E., McDonald, S. , Wilkes, B., Hutchinson, S.J. and Irving, W.L. (2017) Cohort profile: the hepatitis C virus (HCV) research UK clinical database and biobank. International Journal of Epidemiology, 46(5), 1391-1391h. (doi: 10.1093/ije/dyw362) (PMID:28338838)

Thomson, E. et al. (2016) Comparison of next-generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes. Journal of Clinical Microbiology, 54(10), pp. 2470-2484. (doi: 10.1128/JCM.00330-16) (PMID:27385709) (PMCID:PMC5035407)

Foster, G. R. et al. (2016) Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 64(6), pp. 1224-1231. (doi: 10.1016/j.jhep.2016.01.029) (PMID:26829205)